Premium
Gender dimorphism in regulation of plasma proteins in streptozotocin‐induced diabetic rats
Author(s) -
Choi JungWon,
Aseer Kanikkai Raja,
Chaudhari Harmesh N.,
Mukherjee Rajib,
Choi Minji,
Yun Jong Won
Publication year - 2013
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201200529
Subject(s) - sexual dimorphism , streptozotocin , medicine , endocrinology , blood proteins , glycoprotein , biology , diabetes mellitus , proteome , hormone , sex characteristics , serum amyloid p component , insulin , bioinformatics , biochemistry , c reactive protein , inflammation
In the present study, we examined differentially regulated plasma proteins between healthy control and streptozotocin ( STZ )‐induced male and female diabetic rats by 2 DE ‐based proteomic analysis. Animal experiments revealed that significantly lower plasma insulin levels were observed in female diabetic rats, consequently resulting in higher blood glucose levels in female diabetic rats. Importantly, plasma levels of sex hormones were significantly altered in a gender‐dependent manner before and after STZ treatment. Results of the animal experiment indicated the existence of sexual dimorphism in the regulation of plasma proteins between healthy control and diabetic rats. Plasma proteome analysis enabled us to identify a total of 38 proteins showing sexual dimorphic regulation patterns. In addition, for the first time, we identified several differentially regulated plasma proteins between healthy control and diabetic rats, including apolipoprotein E , fetuin B , α‐1‐acid glycoprotein, β‐2‐glycoprotein 1, 3‐hydroxyanthranilate 3,4‐dioxygenase, and serum amyloid P ‐component. To the best of our knowledge, this is the first proteomic approach to address sexual dimorphism in diabetic animals. These proteomic data on gender‐dimorphic regulation of plasma proteins provide valuable information that can be used for evidence‐based gender‐specific clinical treatment of diabetes.